[go: up one dir, main page]

PE20040999A1 - Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas - Google Patents

Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas

Info

Publication number
PE20040999A1
PE20040999A1 PE2003000899A PE2003000899A PE20040999A1 PE 20040999 A1 PE20040999 A1 PE 20040999A1 PE 2003000899 A PE2003000899 A PE 2003000899A PE 2003000899 A PE2003000899 A PE 2003000899A PE 20040999 A1 PE20040999 A1 PE 20040999A1
Authority
PE
Peru
Prior art keywords
inhibitors
cycline
dependent kinases
heteroaryl
refers
Prior art date
Application number
PE2003000899A
Other languages
English (en)
Inventor
Ronald J Doll
Viyyoor M Girijavallabhan
Kamil Paruch
Ray Anthony James
Lawrence W Dillard
Vinh D Tran
Michael P Dwyer
Haengsoon Park
Zhen Min He
Timothy J Guzi
Original Assignee
Schering Corp
Pharmacopeia Drug Discovery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Pharmacopeia Drug Discovery filed Critical Schering Corp
Publication of PE20040999A1 publication Critical patent/PE20040999A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA III DONDE Q ES -S(O2)-, -C(O)-; R ES ARILO, HETEROARILO SUSTITUIDOS O NO; R2 ES ALQUINILO, HETEROARILO, -COOH, ENTRE OTROS; R3 ES H, HALOGENO, ALQUILO, NH2, ENTRE OTROS; R4 ES H, HALO, ALQUILO. SON COMPUESTOS PREFERIDOS: A, B, C, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA SIENDO INHIBIDORES DE CINASA DE PROTEINAS UTILES EN EL TRATAMIENTO DE CANCER, INFLAMACION, ARTRITIS, ENFERMEDADES VIRALES Y ENFERMEDADES NEURODEGENERATIVAS, CARDIOVASCULARES Y FUNGICAS
PE2003000899A 2002-09-04 2003-09-04 Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas PE20040999A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40799902P 2002-09-04 2002-09-04

Publications (1)

Publication Number Publication Date
PE20040999A1 true PE20040999A1 (es) 2004-12-28

Family

ID=31978544

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000899A PE20040999A1 (es) 2002-09-04 2003-09-04 Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas

Country Status (19)

Country Link
US (3) US7074924B2 (es)
EP (1) EP1534710B1 (es)
JP (2) JP4700344B2 (es)
KR (1) KR20050057139A (es)
CN (1) CN1701074A (es)
AR (1) AR041136A1 (es)
AT (1) ATE376548T1 (es)
AU (1) AU2003268385B2 (es)
CA (1) CA2497450C (es)
DE (1) DE60317077T2 (es)
ES (1) ES2291665T3 (es)
IL (1) IL167088A (es)
MX (1) MXPA05002570A (es)
MY (2) MY137888A (es)
NZ (1) NZ539164A (es)
PE (1) PE20040999A1 (es)
TW (1) TWI335919B (es)
WO (1) WO2004022560A1 (es)
ZA (1) ZA200501852B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001124A1 (en) * 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
ATE450534T1 (de) 2002-08-23 2009-12-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte davon, analoga und ihre verwendung
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
ES2291665T3 (es) * 2002-09-04 2008-03-01 Schering Corporation Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas.
WO2004076458A1 (en) * 2003-02-28 2004-09-10 Teijin Pharma Limited Pyrazolo[1,5-a]pyrimidine derivatives
GB0305559D0 (en) * 2003-03-11 2003-04-16 Teijin Ltd Compounds
CA2538026A1 (en) * 2003-09-09 2005-03-24 Ono Pharmaceutical Co., Ltd. Crf antagonists and heterobicyclic compounds
AR049769A1 (es) * 2004-01-22 2006-09-06 Novartis Ag Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina
AU2005281704A1 (en) 2004-09-06 2006-03-16 Nycomed Gmbh Novel pyrazolopyrimidines
FR2876583B1 (fr) * 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
EP1922321A1 (en) * 2005-08-09 2008-05-21 Eirx Therapeutics Ltd Pyrazoloý1,5-a¨pyrimidine compounds and pharmaceutical compositions containing them
CA2621983A1 (en) 2005-09-09 2007-03-22 Schering Corporation Azafused cyclin dependent kinase inhibitors
RU2008139560A (ru) * 2006-03-08 2010-04-20 Новартис АГ (CH) ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ПИРАЗОЛО[1,5a]ПИРИМИДИН-7-ИЛАМИНА ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ НАРУШЕНИЙ
WO2007118844A1 (de) * 2006-04-13 2007-10-25 Basf Se Substituierte pyrazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen sowie sie enthaltende mittel
US8507673B2 (en) * 2008-12-11 2013-08-13 Emory University Process for preparing 5,7 diaminopyrazolo [1,5-A] pyrimidine compounds
EP2417138B1 (en) 2009-04-09 2019-11-27 Merck Sharp & Dohme Corp. Pyrazolo[1, 5-a]pyrimidine derivatives as mtor inhibitors
US8993535B2 (en) 2009-09-04 2015-03-31 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
KR101478889B1 (ko) 2010-02-26 2015-01-02 미쓰비시 타나베 파마 코퍼레이션 피라졸로피리미딘 화합물 및 ｐｄｅ10 억제제로서의 그의 용도
US10953012B2 (en) 2011-04-26 2021-03-23 Bioenergenix Llc Heterocyclic compounds for the inhibition of pask
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2014066743A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
US10392389B2 (en) 2012-10-25 2019-08-27 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
CN107501275B (zh) 2012-12-07 2019-11-22 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物
BR112015022545A2 (pt) 2013-03-13 2017-07-18 Constellation Pharmaceuticals Inc compostos de pirazolo e os usos disso
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2016512239A (ja) 2013-03-15 2016-04-25 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
PT3077397T (pt) 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
JP2017501145A (ja) 2013-12-23 2017-01-12 ノージン ビーブイ Ｃｃｒ９調節因子として有用な化合物
JP6568111B2 (ja) 2014-06-05 2019-08-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ＡＴＲキナーゼ阻害剤として有用な２−アミノ−６−フルオロ−Ｎ−［５−フルオロ−ピリジン−３−イル］ピラゾロ［１，５−ａ］ピリミジン−３−カルボキサミド化合物の放射性標識された誘導体、この化合物およびその異なる固体形態の調製
HRP20191375T1 (hr) 2014-06-17 2019-11-01 Vertex Pharma Postupak liječenja raka upotrebom kombinacije chk1 i atr inhibitora
CN106699785A (zh) * 2015-07-13 2017-05-24 南开大学 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
RU2768621C1 (ru) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
EP3377908B1 (en) 2015-11-18 2020-08-05 Genzyme Corporation Biomarker of polycystic kidney disease and uses thereof
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4116288Y1 (es) 1964-11-07 1966-07-28
JPS6157587A (ja) * 1984-08-29 1986-03-24 Shionogi & Co Ltd 縮合複素環誘導体および抗潰瘍剤
EP0591528B1 (en) 1991-04-22 1998-12-23 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME
JP3275389B2 (ja) * 1991-09-06 2002-04-15 三菱ウェルファーマ株式会社 ４−アミノ（アルキル）シクロヘキサン−１−カルボン酸アミド化合物
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
EP0628559B1 (en) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
GB9325074D0 (en) 1993-12-07 1994-02-02 Zeneca Ltd Bicyclic heterocycles
EP0714898B1 (en) 1994-06-21 2001-11-14 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
JPH10101672A (ja) * 1996-08-06 1998-04-21 Otsuka Pharmaceut Factory Inc アデノシン増強剤
JPH10101671A (ja) * 1996-08-08 1998-04-21 Otsuka Pharmaceut Factory Inc 一酸化窒素合成酵素阻害剤
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
JPH11292879A (ja) * 1998-04-08 1999-10-26 Otsuka Pharmaceut Factory Inc カルボキサミド誘導体
FR2805160B1 (fr) 2000-02-23 2002-04-05 Oreal Compositions pour la teinture d'oxydation des fibres keratiniques comprenant un n(2-hydroxybenzene)-carbramate ou un n-(2-hydroxybenzene)-uree et une pyrazolopyrimidine, et procedes de teinture
JP2002053466A (ja) * 2000-08-08 2002-02-19 Otsuka Pharmaceut Factory Inc アポトーシス調整剤
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
FR2817469B1 (fr) 2000-12-04 2003-04-18 Oreal Composition de coloration, procede d'obtention et utilisation pour la coloration de fibres keratiniques
CA2432417A1 (fr) 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
EP1505068A4 (en) 2002-04-23 2008-03-19 Shionogi & Co PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND INHIBITOR OF NAD (P) H OXIDASE CONTAINING SAID DERIVATIVE
DE10223917A1 (de) 2002-05-29 2003-12-11 Bayer Cropscience Ag Pyrazolopyrimidine
ES2291665T3 (es) * 2002-09-04 2008-03-01 Schering Corporation Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas.

Also Published As

Publication number Publication date
CA2497450A1 (en) 2004-03-18
TWI335919B (en) 2011-01-11
TW200420564A (en) 2004-10-16
NZ539164A (en) 2006-04-28
DE60317077T2 (de) 2008-07-24
ZA200501852B (en) 2005-09-08
US20040116442A1 (en) 2004-06-17
MY137888A (en) 2009-03-31
EP1534710A1 (en) 2005-06-01
IL167088A (en) 2010-12-30
JP4700344B2 (ja) 2011-06-15
US7511049B2 (en) 2009-03-31
JP2006502161A (ja) 2006-01-19
AU2003268385B2 (en) 2006-12-21
WO2004022560A1 (en) 2004-03-18
HK1071569A1 (en) 2005-07-22
ES2291665T3 (es) 2008-03-01
US20060173016A1 (en) 2006-08-03
AR041136A1 (es) 2005-05-04
CN1701074A (zh) 2005-11-23
AU2003268385A1 (en) 2004-03-29
DE60317077D1 (de) 2007-12-06
MXPA05002570A (es) 2005-09-08
JP2010168406A (ja) 2010-08-05
WO2004022560A9 (en) 2005-07-07
US7309705B2 (en) 2007-12-18
EP1534710B1 (en) 2007-10-24
US20070275983A1 (en) 2007-11-29
KR20050057139A (ko) 2005-06-16
MY141978A (en) 2010-08-16
CA2497450C (en) 2011-05-31
ATE376548T1 (de) 2007-11-15
US7074924B2 (en) 2006-07-11

Similar Documents

Publication Publication Date Title
PE20040999A1 (es) Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas
PE20041076A1 (es) Nuevas pirazolopirimidinas como inhibidores de la quinasa dependientes de ciclina
PE20041000A1 (es) Pirazolopirimidinas como inhibidores de la quinasa dependientes de ciclina
PE20040998A1 (es) Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas
PE20070543A1 (es) Pirazolopirimidinas como inhibidores de protein quinasas
EA200600317A1 (ru) Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты)
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
DE60328010D1 (de) Heterocyclische verbindungen
EA200500721A1 (ru) Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA200501009A1 (ru) Замещённые пирролопиразольные производные в качестве ингибиторов киназы
ATE365740T1 (de) Substituierte pyrazolopyrimidine
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
PE20080931A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
SE0202133D0 (sv) Novel compounds
DK1678166T3 (da) Proteinkinaseinhibitorer
EP1633740A4 (en) CHEMICAL COMPOUNDS
SE0402735D0 (sv) Novel compounds
ATE403657T1 (de) Chemische verbindungen
BRPI0416692A (pt) inibidores heterocìclicos de mek e métodos de emprego destes
SE0301700D0 (sv) Novel compounds
SE0302486D0 (sv) Novel compounds
SE0200920D0 (sv) Novel compounds
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas

Legal Events

Date Code Title Description
FC Refusal